When an innovative drug moves from itsfirst patent filing toward global commercialization, the path typicallyinvolves a PCT application, national or regional phase entry, and examinationin multiple jurisdictions. At every stage, patent specifications, claims,sequence listings, chemical structure descriptions, and related technicaldocuments need to convey the same technical information accurately acrosslanguages.
For life sciences companies, however,patent translation is much more than a language exercise.
It requires a deep understanding ofchemical structures and biological sequences, careful handling of claimlimitations, familiarity with patent practice in different jurisdictions, and areliable way to keep multiple language versions of the same patent familyaligned over time.
A single incorrect sequence identifier, aweakened claim limitation, or terminology that changes from one languageversion to another can create unnecessary problems during prosecution, patentportfolio analysis, and ongoing IP management.
For pharmaceutical, biotechnology, andmedical device companies building global patent portfolios, the right questionis therefore not simply whether a translation is accurate. It is whether thetranslation partner has the technical, linguistic, and project-managementcapabilities to handle the complexity of life sciences patents throughout theirlifecycle.
Here are five capabilities companies shouldlook for.
1. A Clear Understanding of Patent Practice AcrossJurisdictions
One of the most easily overlookedchallenges in life sciences patent translation is that the same technicalconcept may be expressed differently depending on the jurisdiction, documenttype, and professional context.
Terminology is one part of the equation.
For pharmaceutical products, for example,International Nonproprietary Names (INNs) are established by the World HealthOrganization (WHO) to provide internationally recognized nonproprietary namesfor pharmaceutical substances. WHO works closely with national nomenclaturecommittees, and national naming systems such as the United States Adopted Names(USAN) and Japanese Adopted Names (JAN) are, with rare exceptions, identical tothe corresponding INNs.
When translating pharmaceutical patentdocuments, the task is therefore not simply to find the "right name"in another language. Translators need to distinguish among the INN, chemicalname, internal development code, and terminology used in related regulatory ortechnical documents, while keeping those relationships consistent throughoutthe project.
The same principle applies to patentterminology.
A term such as "药物组合物" cannot be translated reliably bylooking at the term in isolation. Its English rendering depends on the claimlanguage, the technical context, and the limitations attached to thecomposition. More importantly, the translation needs to preserve thoselimitations—such as ingredients, proportions, intended use, dosage form, orother defining features—without changing their scope.
The surrounding regulatory environmentmatters too.
Patent projects often run in parallel withregulatory submissions, clinical documentation, and technical files. That meansa language services team needs to understand how different types of documentsare used in their respective markets.
In the United States, for example, the FDAuses the Electronic Common Technical Document (eCTD) as the standard format forapplications, amendments, supplements, and reports submitted to the Center forDrug Evaluation and Research (CDER) and the Center for Biologics Evaluation andResearch (CBER). This includes submissions such as NDAs, ANDAs, BLAs, and INDs.
Medical device submissions follow adifferent process. The FDA's eSTAR program is used for applicable 510(k) and DeNovo submissions, among other medical device submission types, and the currentprogram has its own submission formats and version requirements.
These distinctions are important becausepatent translation does not happen in a vacuum. Translators and reviewers needto understand the target jurisdiction, the purpose of the document, and theterminology conventions that apply to it.
In our experience, many downstream issuesbegin before translation even starts. Problems can arise when a project doesnot clearly distinguish among target markets, document types, historicalterminology, and the client's existing language assets.
A strong workflow therefore starts withreference-material review: identifying where the documents will be used,understanding the client's existing terminology, and establishing the languageand review requirements before translation begins.
That preparation can make a significantdifference to the consistency of every version that follows.
2. Precise Handling of Claims and Legal Limitations
The specification explains the inventionand provides technical disclosure. The claims, by contrast, define what theapplicant seeks to protect. That makes claim translation one of thehighest-risk areas in a life sciences patent project.
The challenge is not whether a sentencesounds polished. It is whether the translated claim preserves the originaltechnical and legal limitations.
English patent claims provide many goodexamples.
Terms such as "comprising,""consisting essentially of," and "consisting of" are notinterchangeable. The USPTO treats them as transitional phrases with differenteffects on claim scope. "Comprising," for example, is open-ended anddoes not exclude additional, unrecited elements or steps, while"consisting of" is closed. The interpretation of these transitionalphrases ultimately depends on the facts and circumstances of the specific case.
That is why patent translation cannotsimply rely on a general dictionary, a generic translation memory, or asentence-level machine translation.
Markush claims provide another goodexample. Pharmaceutical and chemical patents frequently use language such as"selected from the group consisting of ..." to define alternativeswithin a claimed group of compounds, chemical groups, or other technicaloptions. Translators need to preserve not only the wording of the list, butalso its logical relationships and any structural limitations establishedelsewhere in the document.
The highest-risk errors are often subtle.
A translation may read perfectly well whilechanging the scope or relationship of a limitation.
Particular attention should be paid to:
- quantitative limitations such as "atleast," "no more than," and "about";
- hierarchical wording such as"optionally," "preferably," and "furthercomprising";
- logical relationships expressed through"and," "or," and "and/or";
- limitations relating to structure,function, intended use, or dosage;
- defined terms and their relationship to thecorresponding definitions in the specification.
These expressions may look minor inisolation, but in a claim they can have a very specific legal and technicalfunction.
That is why claim review needs to go beyondlanguage fluency. Reviewers should work through each limitation, logicalrelationship, and defined term against the source text and the surroundingdisclosure.
Claims also tend to require more humanreview than general descriptive content. When a patent family spans severallanguages, side-by-side comparison becomes particularly important to ensurethat key limitations have not shifted between versions.
For life sciences companies, this is one ofthe clearest areas where specialist patent translation can make a practicaldifference.
3. Accurate Handling of Sequences, Chemical Structures,and Technical Data
Life sciences patents contain types oftechnical information that do not appear as frequently in other technologyareas: nucleotide and amino acid sequences, chemical structures, experimentalparameters, biological mechanisms, and detailed cross-references among them.
The challenge is that these elements areinterconnected. A sentence can be linguistically correct while the technicalrelationships across the document are no longer correct.
Sequence listings are a good example.
WIPO Standard ST.26 came into force on July1, 2022, replacing the earlier ST.25 framework for applicable filings. Underthe current rules, patent applications filed on or after July 1, 2022 thatdisclose nucleotide or amino acid sequences must contain an ST.26-compliant XMLsequence listing. WIPO provides WIPO Sequence, a dedicated tool for creatingand validating compliant sequence listings.
WIPO has also announced that version 2.0 ofST.26 will enter into force on July 1, 2027, making it important for teamshandling long-running patent portfolios to keep track of changes to thestandard.
The sequence itself is generally notsomething to translate. The surrounding information is.
Annotations, functional descriptions,sequence names, variation information, and references to sequence identifiersin the specification and claims all need to remain consistent.
For example, if a claim refers to "SEQID NO: 1," the corresponding reference in the specification and sequencelisting must point to the same sequence. An incorrect identifier—or aninaccurate description of sequence identity or variation—can affect how therelevant disclosure and claim are understood.
The same principle applies tocross-references among the specification, claims, sequence listing, figures,tables, and examples.
Chemical structures require the same levelof care.
In a pharmaceutical chemistry patent, acompound name is not simply a technical term that can be replaced with adictionary equivalent. Substituent positions, stereochemistry, chiral centers,ring structures, and connectivity all correspond to specific structuralinformation.
IUPAC nomenclature, internal compoundnumbers, and structural representations therefore need to remain alignedthroughout the document.
This is where subject-matter expertisebecomes critical. Reviewers need enough knowledge of chemistry, pharmaceuticalscience, or molecular biology to identify problems that may not be obvious fromthe language alone.
In project work, we often see cases wherethe translation itself appears fluent, but the technical information hasshifted—for example, when a sequence identifier no longer matches the maintext, a compound name does not fully correspond to its structural description,or an experimental parameter differs slightly across language versions.
These problems occur at the intersection oflanguage and technical information, which is why conventional linguisticproofreading is not always enough.
Life sciences patent QA therefore needs toask two questions: Is the language accurate, and do the technical elementsremain correctly connected?
4. The Right Balance Between AI and Specialist Review
AI is becoming a practical part of patenttranslation workflows. The more useful question for life sciences companies isno longer whether AI can be used, but where it adds value—and where specialistjudgment still needs to take the lead.
AI can be highly effective when the contentis repetitive, structured, and relatively predictable. Background sections,routine technical descriptions, and standardized passages may be suitable forpreprocessing or draft generation.
High-risk content is different.
Claims, complex chemical names,experimental data, sequence-related descriptions, and legally significantlimitations require much closer human review.
The issue is not simply that AI can makelanguage mistakes. In life sciences patents, accuracy often depends onrelationships between terms, structures, definitions, and earlier documents. Asentence that sounds natural may still be technically wrong.
Consider a chemical abbreviation. Dependingon the context, it may refer to a substituent, an experimental condition, or aninternal compound code. Its correct interpretation cannot be determined fromlanguage fluency alone.
The same applies to functional limitations.A sentence may be grammatically perfect while failing to preserve the fullscope of the original technical limitation.
This is why we see AI changing the workflowrather than replacing specialist judgment.
The practical approach is to divide thework according to risk and suitability:
- AI handles efficiency.
- Subject-matter experts make the criticaljudgments.
- QA checks the final result.
This model allows automation to take onrepetitive work while keeping high-risk decisions in the hands of specialists.
For life sciences patent projects, thatdistinction matters more than simply adding AI to the workflow.
5. Maintaining Consistency Across Multilingual PatentFamilies
For companies building global patentportfolios, one patent rarely remains a single-language document.
A PCT application may move into national orregional phases in multiple jurisdictions, with each Office evaluating theapplication under its own national or regional law and procedures. Depending onthe jurisdiction, the process may also require translated application materialsand subsequent prosecution documents.
As the portfolio expands, companies need tomanage specifications, claims, examination responses, amendments, and relatedpatent documents across languages and jurisdictions.
This is where the meaning of"consistency" becomes important.
Consistency does not mean making everylanguage version a word-for-word copy.
Core technical information needs to remainstable: compound names, biological targets, sequence identifiers, indications,key parameters, and core technical concepts should continue to refer to thesame underlying information.
At the same time, claim language and legalexpression may need to reflect the conventions and examination practices of thetarget jurisdiction.
The objective is therefore technicalconsistency with appropriate linguistic and jurisdictional adaptation.
Without a proper terminology andversion-management process, inconsistencies can accumulate quietly.
A compound may appear under different namesin different language versions. A target may be abbreviated differently fromone project to another. A key claim term may change during a laternational-phase translation.
Each discrepancy may seem insignificant atfirst. Over time, however, they make patent searching, document comparison,prosecution, and portfolio management more difficult.
The challenge in a long-running patentfamily is often not the first translation. It is everything that comesafterward.
As new countries, languages, examinationdocuments, and amendments are added, the language baseline needs to evolve withthe portfolio.
That is why terminology management andversion control should begin with the first translation, rather than beingintroduced only after inconsistencies appear.
A well-managed linguistic asset can thencontinue to support the patent family as it moves through additionaljurisdictions and later stages of prosecution.
6. From One-Time Translation to Long-Term Patent LanguageManagement: How Glodom Supports LifeSciences Projects
The five areas above describe thechallenges companies need to consider when choosing a life sciences patenttranslation partner. The next question is how those requirements should betranslated into day-to-day project execution.
For Glodom, the answer starts with lookingbeyond a single document.
A global patent program may involvemultiple documents, languages, jurisdictions, and filing stages over manyyears. Our approach is therefore built around the broader patent lifecyclerather than treating translation as a one-off source-to-target task.
6.1 Establishing a Project Language Baseline from theStart
We begin by reviewing the client's existingpatent documents, previous translations, and internal language assets.
Core terminology, compound names, targets,indications, sequence identifiers, and important claim expressions can then beorganized into a consistent project baseline.
For clients with an establishedinternational patent portfolio, historical translations can also be reviewed toidentify terminology differences across jurisdictions or translation batches.
The goal is not to force every languageversion into identical wording. It is to keep the underlying technicalinformation stable while allowing the language to follow the requirements ofeach market.
6.2 Building Specialist Teams Around the Technology
Life sciences covers a broad range oftechnologies, and the translation requirements vary accordingly.
Small-molecule pharmaceuticals, biologics,cell and gene therapies, and medical devices each involve differentterminology, technical concepts, and documentation.
Glodom therefore builds project teamsaround the technical requirements of the work. Depending on the assignment,specialists may need to handle chemical structures, biological sequences,mechanisms of action, experimental data, or patent-specific language.
Higher-risk content—such as claims,structural descriptions, and sequence-related information—can then receiveadditional review and cross-checking.
This helps reduce the risk of technicalinformation being lost or distorted during cross-language transfer.
6.3 Applying AI and Human Review According to Risk
Glodom uses AI where it can improveefficiency without compromising professional judgment.
Depending on the project, AI can supportterminology retrieval, repetitive content processing, draft generation, andselected QA checks.
At the same time, higher-risk contentreceives focused specialist review.
Claims, complex chemical names,experimental data, and critical technical descriptions require a level ofcontextual judgment that cannot be reduced to language-model output alone.
The result is a workflow in whichautomation takes care of appropriate repetitive tasks, while specialists remainresponsible for the decisions that matter most.
6.4 Maintaining Terminology and Versions Across the PatentFamily
As a portfolio expands into additionaljurisdictions, language management also becomes more complex.
Glodom maintains multilingual terminologyresources and project-version information so that new national-phasetranslations, examination documents, and subsequent amendments can be alignedwith the established language baseline.
For long-term projects, this approach alsoreduces repeated clarification and the need to reconstruct historicalterminology decisions.
Each new translation can build on thelanguage assets created through earlier work.
6.5 Connecting Translation, Review, and QA
The final piece is making sure theseactivities work as one quality process.
A project may begin with terminology andreference-material review, move into specialist translation, and then proceedthrough targeted review of claims, sequence information, chemical structures,and other high-risk content.
QA and consistency checks then provide anadditional layer of verification, while terminology resources are updated tosupport subsequent work.
With more than 20 years of experience inlanguage services, Glodom has accumulated specialized language resources,terminology assets, and project experience across the life sciences sector.
By combining specialist teams, languagetechnology, and project management, Glodom provides multilingual patenttranslation, related technical documentation services, and long-term languagemanagement for patent families.
For companies advancing global R&D andIP strategies, the focus goes beyond whether a translation is delivered ontime.
The goal is to make sure that everytranslated document can function as a reliable part of the company's broaderglobal patent portfolio—accurate, consistent, and manageable over time.
Conclusion
The hardest part of life sciences patenttranslation is rarely the vocabulary itself.
The real challenge is preserving technicalinformation, claim limitations, and relationships across a patent family whendocuments move between languages, disciplines, and jurisdictions.
For that reason, companies evaluating alife sciences patent translation partner should look beyond language accuracyalone.
Five capabilities deserve particularattention:
- Understanding patent practice andprofessional context across jurisdictions
- Accurately preserving claims and legallimitations
- Handling sequences, chemical structures,and other high-precision technical information
- Using AI where it adds value whileretaining specialist human judgment
- Maintaining consistency acrossmultilingual patent families over time
For innovative pharmaceutical,biotechnology, and medical device companies expanding into global markets,patent translation should not be treated as a one-time task attached to afiling deadline.
It is part of the broader process ofmanaging intellectual property across languages and jurisdictions.
With more than 20 years of experience inlanguage services, Glodom combines specialist expertise, language technology,and project management to support multilingual patent documentation andlong-term patent-family language management.
As global patent portfolios grow, we helpcompanies keep their technical information accurate, consistent, and traceableacross languages, documents, and markets.
